Vircell Showcases Its Powerful Automation System and Immunoassay Testing Kits at MEDICA 2021
By LabMedica International staff writers Posted on 15 Nov 2021 |
Image: VirClia® Lotus (Photo courtesy of VIRCLIA)
Vircell (Granada, Spain) exhibited its powerful automation system and immunoassay testing kits at this year's MEDICA, the world's largest annual medical technology trade fair, which took place from 15-18 November in Düsseldorf, Germany.
Vircell is a microbial biotechnology company which develops, manufactures and markets ready-to-use kits for the diagnosis of esoteric infectious diseases. It is specialized in the development and production of ready-to-use reagents for the diagnosis of infectious diseases in humans by different techniques – ranging from the traditional cell culture to the most innovating developments in the field of molecular biology.
At MEDICA 2021, Vircell presented VIRCLIA, its powerful automation system with a built-in reader, intelligent racks and intuitive software. The VIRCLIA automation system offers 192 patient sample positions and fully-automated reader options (EIA or CLIA+EIA). It features a probe-mounted camera for real-time process monitoring and remote diagnostics, along with a built-in barcode reader for streamlined loading and lower sample tracking errors.
Among the immunoassay testing kits showcased by Vircell at the event was the Chlamydia ELISA indirect immunoenzyme assay to test antibodies against chlamydia in human serum/plasma which is suitable for automated ELISA systems. Vircell also highlighted Pneumobact IFA, an indirect immunofluorescent assay kit to simultaneously test IgG or IgM antibodies against the main ethiological bacterial agents causing respiratory tract infections: Legionella pneumophila sero group 1, Mycoplasma pneumoniae, Coxiella burnetii, Chlamydophila pneumoniae and Chlamydophila psittaci. The kit enables simultaneous detection of the main bacteria causing atypical pneumonia and easy results reading.
Related Links:
Vircell
Vircell is a microbial biotechnology company which develops, manufactures and markets ready-to-use kits for the diagnosis of esoteric infectious diseases. It is specialized in the development and production of ready-to-use reagents for the diagnosis of infectious diseases in humans by different techniques – ranging from the traditional cell culture to the most innovating developments in the field of molecular biology.
At MEDICA 2021, Vircell presented VIRCLIA, its powerful automation system with a built-in reader, intelligent racks and intuitive software. The VIRCLIA automation system offers 192 patient sample positions and fully-automated reader options (EIA or CLIA+EIA). It features a probe-mounted camera for real-time process monitoring and remote diagnostics, along with a built-in barcode reader for streamlined loading and lower sample tracking errors.
Among the immunoassay testing kits showcased by Vircell at the event was the Chlamydia ELISA indirect immunoenzyme assay to test antibodies against chlamydia in human serum/plasma which is suitable for automated ELISA systems. Vircell also highlighted Pneumobact IFA, an indirect immunofluorescent assay kit to simultaneously test IgG or IgM antibodies against the main ethiological bacterial agents causing respiratory tract infections: Legionella pneumophila sero group 1, Mycoplasma pneumoniae, Coxiella burnetii, Chlamydophila pneumoniae and Chlamydophila psittaci. The kit enables simultaneous detection of the main bacteria causing atypical pneumonia and easy results reading.
Related Links:
Vircell
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans